Nio's American depositary receipts rose 8.6% to end at a record $58.92. by Jung Min-seo. Shares are priced at $10.94 with an average price target of $19, giving the stock ~60% one-year upside potential. SoftBank Group Corp's Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics in its latest healthcare investment. The two additional Buy ratings provide the stock with a Strong Buy consensus rating. Using TipRanks database, we pinpointed two such stocks. While down year-over-year, this was up 40% sequentially.Despite all of the headwinds facing the oil industry over the past 18 months, XOM has kept its dividend reliable, and paid out the most recent distribution in December 2020. Company profile page for Rani Therapeutics LLC including stock price, company news, press releases, executives, board members, and contact information Apollo has investments in 147 companies, with average exposure of $15.9 million. Q3 revenues and earnings came in under expectations, and fell year-over-year. Plug shares up 1,290% in the past year and currently trade at 67.1 times sales.Benzinga's Take: Of the three $1 million-plus Plug option trades on Friday morning, two were for contracts expiring on Friday, suggesting little about where the buyers and sellers see the stock going in the medium or longer-term.The $1.19 million call purchase may be the most telling of all given the contracts have a break-even price of $54.50, suggesting another 3.2% upside for Plug over the next two-plus months.See more from Benzinga * Click here for options trades from Benzinga * Here's How The US Steel Industry Is Getting Greener * Michael Burry To Tesla Investors: 'Enjoy It While It Lasts'(C) 2021 Benzinga.com. The company's flagship drug candidate is VRDN-001, an anti-IGF-1R monoclonal antibody in clinical-stage research as a treatment for thyroid eye disease (TED). Here are a handful of the biggest: * At 9:36 a.m., a trader sold 1,000 Plug call options with a $36 strike price expiring on Friday near the bid price at $15.50. About Pear TherapeuticsPear Therapeutics is the leader in prescription digital therapeutics, or PDTs. With an average price target of $121, investors stand to take home a 33% gain, should the target be met over the next 12 months. What Happened: The billionaire investor dished out the advice on CNBC's Halftime show saying he could not understand "why people are so focused on selling things that work. "Gold is having a major fundamental shift for many investors and they're starting to abandon their safe haven trade for gold," said Edward Moya, senior market analyst at OANDA. B y Sam Nussey. Benzinga does not provide investment advice. The latest financing was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, The Bridge Builders Collaborative and EDBI. Strategic Education is the owner of two online universities, Capella and Strayer, as well as several coding schools, including DevMountain, Generation Code, and Hackbright Academy. Morgan Stanley now owns 792,627 shares in the company best known for using its treasury funds to load up on bitcoin. Cheap stocks are suddenly in favor. BlueCity provides an avenue of connection for users to link with each other with service providers and platforms. The award program received over 3,750 nominations from around the world this year. 2013. Notable Investors. TOKYO, Dec 8 (Reuters) - SoftBank Group Corp's 9984.T Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics … 4 weeks SoftBank leads $80 million round in healthcare startup Pear Therapeutics Investing.com . 0 . pic.twitter.com/T277d4CByO> > -- Cassandra (@michaeljburry) January 7, 2021Burry is sticking to his bearish guns in a week that multiple Wall Street Tesla bears have finally thrown in the towel and upgraded the stock. Since that date, the stock is up another 48.3%, but Burry said Thursday he's still convinced the Tesla story will ultimately end poorly.> Well, my last Big Short got bigger and Bigger and BIGGER too....$TSLA $60 billion increase in market cap today alone...1 GM, 2 Hersheys, 3 Etsys, 4 Dominos, 10 Vornados...enjoy it while it lasts. FiercePharmaAsia—Takeda’s CMV, leukemia knowledge; COVID-19 vaccines from Sinovac, Clover and Sinopharm. (To watch Silber’s track record, click here)Over the past 3 months, only two other analysts have thrown the hat in with a view on STRA. SoftBank Group Corp's Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics in its latest healthcare investment. The leader in Prescription Digital Therapeutics. In our view, this is likely enough to lift the shares a bit higher and lessen worries about dividend sustainability.”In light of his comments, Read rates XOM shares an Overweight (i.e. Buy), and his $126 price target implies an upside of 39% in the next 12 months. Aspiring to be the global leader in p53-targeted cancer therapies. Given the relative complexity of the options market, large options traders are typically considered to be more sophisticated than the average stock trader.Many of these large options traders are wealthy individuals or institutions who may have unique information or theses related to the underlying stock.Unfortunately, stock traders often use the options market to hedge against their larger stock positions, and there's no surefire way to determine if an options trade is a standalone position or a hedge. "We saw a tremendous opportunity to work with the SoftBank team closely to really think about and execute upon ex-U.S. geographic expansion," said Corey McCann, CEO of Pear Therapeutics. Yet tax increases and greater regulation also loom under Biden. * At 10:23 a.m., a trader bought 1,152 Plug put options with a $49 strike price expiring on Feb. 19 near the ask price at $5.295. Investors need to look beyond the chaos to economic growth as more stimulus arrives and the pandemic recedes. (To watch Read’s track record, click here)That Wall Street still views the energy industry with a cautious eye is clear from XOM’s analyst consensus rating -- Hold. Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. 12 Cheap Stocks Will Be 2021's Fastest Growing, Analysts Say. "He urged investors to get behind Musk, Jeff Bezos, the CEO of Amazon.com, Inc (NASDAQ: AMZN), and Anthony Noto, the CEO of SoFi.See Also: SoFi Merging With Palihapitiya-Backed IPOE SPAC"You get behind these people who have [an] incredibly strong character, who know what they're doing who aren't going to bend to short-term profits, and are just going to drive the train for 10 or 20 years and make the world a better place," said Palihapitiya.The former Facebook Inc (NASDAQ: FB) executive pointed to fellow venture capitalist Bill Gurley of Benchmark who has a great phrase, "when the music's on you gotta dance. Could This Be Next? Pear is pioneering a completely novel approach to treating disease by developing and delivering clinically validated software-based therapeutics. Home Tag Pear Therapeutics. SEC.report. Both Democratic candidates won Senate seats, giving the incoming Biden Administration the ability to push policies through Congress over any opposition – at least for the next two years.This Democrat victory, ensuring short-term one-party control of the Presidency and Congress, has Stoltzfus worried. The total revenues hit $43.8 million. The monoclonal antibody is about to enter Phase 2 clinical trial, with initial results expected around mid-year 2021.miRagen is funding its current research with a $91 million capital raise, arranged in a private placement financing agreement. Our cross-functional team operates at the intersection of biology and software technology. "Palihapitiya described Tesla CEO Elon Musk as a "guy who has consistently been one of the most important entrepreneurs in the world. miRagen acquired the rights to VRDN-001 late last year, after its October acquisition of Veridian Therapeutics. * At 10:40 a.m, a trader bought 486 Plug call options with a $30 strike price expiring on Mar. Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. An improving economic backdrop, plus higher sales and earnings, could bring a surge in dividends and buybacks this year. Shares are selling for $18.26 and have an average price target of $32. miRagen Therapeutics (MGEN)miRagen Therapeutics aims to develop new treatment options for diseases that today’s therapies cannot adequately ameliorate. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. He writes of the company’s current situation, “STRA reported 3Q20 mixed results, with Strayer enrollments underperforming, offsetting improving Capella enrollments and cost management… While the ‘outlook’ was disappointing, we are cautiously optimistic that the trend will get ‘less worse’ through 2021.”Looking ahead, Silber believes that STRA’s diverse schools offer some buffer for the current economy – an overall positive for the company. Michael Burry, who was depicted by Christian Bale in 2015's "The Big Short," said he was shorting Tesla Inc (NASDAQ: TSLA) in December. Pear said PDTs are a new therapeutic class that uses software to directly treat serious disease, alone or in combination with drugs. Pear Announces Availability of reSET® and reSET-O® to Wellpath Community Care Center Patients These stocks, whose prices are hitting bottom, present investors with a choice and an opportunity. Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. This isn't only a sign that investors are assured of bigger returns or a future Pear Therapeutics stock, but a sign that digital therapeutics may just be the future of medicine. Here's a list of 22 stocks expecting 100% to 800% EPS growth. MedTech Breakthrough is an independent market intelligence organization that recognizes top companies, technologies, and products in the global health and medical technology market. TOKYO (Reuters) - SoftBank Group Corp's Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics … Get behind them don't sell a share just let them create value," advised Palihapitiya.Why It Matters: Palihapitiya repeated his thesis that Tesla is a disruptive company whose primary value is about "deregulating energy" and is not just an automaker.The investment guru made a "fairly large" investment in Tesla in 2016 and has said that Tesla would become a trillion-dollar company on the scale of Apple Inc (NASDAQ: AAPL).Price Action: On Thursday, Tesla shares closed nearly 7.9% higher at $816.04 and rose 1.65% in the after-hours session to $829.50. OUR COMPANY. Since then, Apollo has amended its revolving credit facility by extending maturity to December 2025.On the dividend front, Apollo has maintained its payments to regular shareholders despite the corona pandemic. This target implies a 75% upside from current levels. Buy) rating with a $62 price target, implying a one-year upside potential of 88%. (See GSBD stock analysis on TipRanks)ExxonMobil (XOM)From BDCs we’ll move on to the oil industry. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Will they go even higher? (See STRA stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. "The length of time that households and economies have been negatively impacted by the spread of the virus across the world in our view will likely result in less resistance to inoculation against Covid-19 than many experts had feared early on in the pandemic. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Plug Power Inc (NASDAQ: PLUG) shares jumped another 10% on Friday after the company announced a new partnership with South Korean industrial company SK Group.A flurry of large Plug option trades were mixed in nature on Friday as investors decide what to make out of the stock's two-day surge.The Plug Trades: On Friday morning, Benzinga Pro subscribers received dozens of option alerts related to unusually large trades of Plug options. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Prescription Digital Therapeutics. (To watch Lau’s track record, click here)Overall, this company has 3 recent reviews on record, and they are all to buy, making the Strong Buy analyst consensus unanimously positive. Pear Therapeutics | 8,112 followers on LinkedIn. Pear Therapeutics, Inc. today announced publication of real-world data analyzing healthcare resource utilization for reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD), in the peer-reviewed journal Expert Review of Pharmacoeconomics & Outcomes Research. Apple could follow the approach of Tesla Inc. (NASDAQ: TSLA) and bring everything in-house.Click here to check out Benzinga's EV Hub for the latest electric vehicles news.2 SPACs To Watch: The news of Hyundai being a potential partner for Apple could put attention on two electric vehicle-related SPACs.Canoo (NASDAQ: GOEV) has a platform that can be used by a variety of electric vehicles. Biden promised checks "immediately" if Democrats won Senate control — and they have. The stock is selling for $11.17, and its $11.50 average price target suggests a modest 3% upside. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear Therapeutics has raised $207.77 m in total funding. These companies offer specialty financing to the middle market, providing credit and funding for small to medium business customers who would otherwise have difficulty accessing capital markets.Apollo Investment is a typical example, with an investment portfolio valued at $2.59 billion. Novartis has moved into the emerging digital therapeutics sector through a deal (PDF) with the pioneering Pear Therapeutics. By year’s end, the stock was trading its January 2020 levels.In November, the company felt confident enough to price an offering of $500 million in unsecured notes, at interest of 2.875% and due in January 2026. Here Comes Joe Biden’s Washington. To do this the Boston, MA-based company closed an $80 million Series D round. Pear’s second product, reSET-O®, for the treatment of Opioid Use Disorder, was the first PDT to receive Breakthrough Designation. December 12, 2020. Pear’s third product, Somryst™ for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. The trade represented a $1.19 million bullish bet.Related Link: Tesla Option Traders Are Dumping Massive Amounts Of CallsWhy It's Important: Even traders who stick exclusively to stocks often monitor option market activity closely for unusually large trades. The funds raised will be used to pay down the revolving credit facility, improving interest on existing debt.Also in November, GSBD reported 80 cents EPS for the quarter ending September 30. Buy) rating, and a price target which, at $12.50, implies a 12% upside from current levels. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors. Benzinga does not provide investment advice. All rights reserved. Oric Pharmaceuticals, a clinical-state biopharma research company, is working on treatments to overcome cancer resistance.Oric’s lead candidate is ORIC-101, which shows promise as a glucocorticoid receptor (GR) antagonist. By Sam Nussey. ""So these guys are dancing they are in rhythm they're in flow let them do their thing. Active, Closed, Last funding round type (e.g. The company offers a range of online services, including online dating, entertainment, health consulting, online pharmacy, and family planning. B y Sam Nussey. Company profile page for Rani Therapeutics LLC including stock price, company news, press releases, executives, board members, and contact information Each is down significantly, but each also has enough upside potential to warrant a Buy rating.BlueCity Holdings (BLCT)We will start with an online platform and community service company, focused on the LGBTQ (lesbian, gay, bisexual, and transgender) audience. The trade represented a $1.55 million bearish bet. 5 Years From Now, You'll Probably Wished You Grabbed This Stock. September 23, … (To watch O’Shea’s track record, click here)Overall, Apollo has two reviews on record, and they are split – 1 Buy and 1 Hold – for a Moderate Buy consensus view. Ways to Invest in Pear Therapeutics stock. Invest in proven BioTech companies like Pear Therapeutics at SharesPost.com. Editor's Note: This story has been updated with additional quotes from Pear Therapeutics. Tag: Pear Therapeutics. And a growing group of them, including some in the S&P 500, are actually seen putting up huge profit growth this year. Hyundai confirmed the talks and later backtracked saying it talked to numerous automakers.The launch of the Apple Car is several years away, according to recent reports. Using TipRanks’ database, we learned that the rest of the Street is in agreement, as all three boast a “Strong Buy” analyst consensus. Consider These Stocks and Funds for Your Portfolio. We expect membership to contribute 21% revenue in '22E, which could raise valuation as the model has better retention, margins, and visibility," Pei noted.The analyst added, "Despite about 50% of its users being located outside of China, they only accounted for ~10% of BLCT’s total revenue, as overseas monetization features have only been recently launched. Pear’s products reSET and reSET-O for the treatment of substance use disorder and opioid use disorder, respectively, are the first two PDTs to receive market authorization to treat the disease from FDA. DeGeeter backs his Outperform (i.e. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. His $20 price target supports his bullish stance, and suggests a robust 97% upside for 2021. The ADRs traded as high as $59.31, an intraday record. Pear Therapeutics looks to change all of that, beginning with its PDT to treat substance abuse. Triterras provides an online trading and trade finance platform, Kratos, based on blockchain technology. BLCT sees positive feedback as it ramps up monetization efforts, and we expect its overseas revenue contribution to increase to 21% in ‘22E. Virgin Galactic Holdings Inc (NYSE: SPCE) Chairman and SPAC king Chamath Palihapitiya said Thursday that Tesla Inc (NASDAQ: TSLA) stock could double or triple in value from here. PDTs directly treat diseases, demonstrate safety and efficacy in randomized clinical trials, receive labeled claims from FDA, and are available only by prescription. Pear Therapeutics General Information Description. ... Bank of America Corp. stock falls Tuesday, underperforms market. Pear Therapeutics. Shares of China-based electric-vehicle maker Nio Inc. and alternative-energy company Bloom Energy Corp. were among the top gainers Friday, on continued optimism that clean-energy and related companies would benefit from climate initiatives in the new Biden administration. Pear Therapeutics Stock. The shares are selling for $45.15, and their $47.33 average price target suggests a modest upside of ~5% (See XOM stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. SoftBank Group Corp's Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics in its latest healthcare investment. Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. The current yield is an impressive 11.6%.Covering AINV for Well Fargo, analyst Finian O’Shea noted, “Legacy’s impact has whittled away, adding just $3 million to the top line this quarter, for an annualized yield on FV of ~5.5%. Gold accelerated its slide below the $1,900 mark on Friday, slumping around 3% and dragging down other precious metals as a jump in U.S. Treasury yields hammered bullion's safe-haven appeal. TOKYO, Dec 8 (Reuters) - SoftBank Group Corp's 9984.T Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics … Benzinga does not provide investment advice. The MedTech Breakthrough organization performs one the deepest evaluations of the digital health and medical technology industry landscape, with the aim of selecting and highlighting innovative solutions and companies that address a true need, solve a complex or critical problem, or seize an opportunity and create or revolutionize a new market or industry. In his first note of the new year, Stoltzfus notes a series of factors that are going to impact the markets. Since the company's founding, it has already raised $134 million in investments. Benefits information above is provided anonymously by current and former Pear Therapeutics employees, and may include a summary provided by the employer. Form D Pear Therapeutics, Inc. Notice of Exempt Offering of Securities, item 06b. Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. All rights reserved. FiercePharmaAsia—Takeda’s CMV, leukemia knowledge; COVID-19 vaccines from Sinovac, Clover and Sinopharm. Modern drug research is expensive, and Oric recently raised capital through a successful public offering of stock. Pear Therapeutics announced that it successfully closed an $80 million Series D financing led by SoftBank Vision Fund 2 with participation from existing investors including Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox, and EDBI, and new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management. That is based on 10 reviews, including 3 Buys, 6 Holds, and 1 Sell. He’s pinpointed 23 recommendations that went on to soar 1,000% or more. PDTs hold tremendous potential to provide better quality of care, increase access to care, and help redefine standard of care for the treatment of serious disease for patients around the world.". H.C. Wainwright said Plug could now generate $12.9 billion in annual revenue and $3.9 billion in annual operating profit by 2030.Of course, the million-dollar question for clean energy investors sitting on massive gains in a stock like Plug Power is whether or not now is the time to finally cash out of the red-hot stock. Predictability is good for the markets, and we’re likely to have that, at least until 2022. (C) 2021 Benzinga.com. This figure implies a 5% upside from current levels. TOKYO (Reuters) – SoftBank Group Corp’s Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics in its latest healthcare investment. In this case, given the relatively large size of the largest Plug trades they could certainly be institutional hedges.South Korea Optimism: Wednesday's Plug Power deal involves SK Group taking a 10% stake in Plug for $1.5 billion, or about $29.29 per Plug share.Plug shares skyrocketed on Thursday and Friday because investors are optimistic the new deal will get Plug's foot in the door of South Korea's "Hydrogen Economy Roadmap" plan. The content is intended to be used for informational purposes only. Novartis. Boston MA, US. The 20,000 square feet factories cost $45 million to make and can produce around 10,000 electric vans a year.With Apple's existing locations around the world, microfactories could be a way for the company to quickly scale production of an electric vehicle.Price Action: Hyundai rallied on the report with shares up 31% to $55.26, hitting new 52-week highs Friday.Canoo and CIIG Merger shares are up 2% and 1%, respectively.See more from Benzinga * Click here for options trades from Benzinga * Future FinTech Group's Stock Is Skyrocketing As A Bitcoin Play * PS5 A Major Catalyst For This Small Cap Video Game Stock; Could Xbox Be Next? TOKYO, Dec 8 (Reuters) – SoftBank Group Corp’s Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics in its latest healthcare investment. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. (See ORIC stock analysis on TipRanks)Triterras (TRIT)Next up is a unicorn, a billion-dollar fintech startup that has been on the public markets for less than three months. About Pear Therapeutics Stock. $270M. Search job openings at Pear Therapeutics. "We saw a tremendous opportunity to work with the SoftBank team closely to really think about and execute upon ex-U.S. geographic expansion," said Corey McCann, CEO of Pear Therapeutics. The company has closed three rounds of private fundraising to-date: most recently, an $80 million Series D in December 2020; a $64 million Series C in January 2019; a $50 million Series B in December 2017; and a $20 million Series A in February 2016. The COVID vaccines coming available and, according to U.S. President-elect Joe Biden, a bigger round of coronavirus stimulus is on the way.But even in a rising market, it’s still possible to find some stocks that haven’t yet joined in the general gains. The poster child of digital therapeutics-pharma collaborations is soon to be no more, as Novartis division Sandoz announced that it is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics back to Pear Therapeutics. Home Tag Pear Therapeutics. Spot gold fell as low as $1,849.55 and was last down 2.8% at $1,858.89 per ounce at 10:53 a.m. EST (1553 GMT). In prescription digital Therapeutics, Inc. with the security and exchange commission or! Most important entrepreneurs in the company offers a range of online services, including 3 Buys, 6 Holds and! Soon could you get yours an avenue of connection for users to link with each other with service and! The drug is entering two separate Phase 1b trials, one for prostate pear therapeutics stock! Implies a 12 % upside from current levels company offers a range of online,. Markets, and his $ 126 price target suggests a modest 3 % upside current! Other with service providers and platforms the leader in prescription digital Therapeutics we are pioneers in.! Have that, beginning with its PDT to receive Breakthrough Designation online services, including insurance,. Very important to do your own analysis before making any investment mission is clear: we are in! Biden 's $ 2,000 stimulus checks: How soon could you get yours cross-functional team operates at the of. Takes 2 minutes to see top 5 lenders that will likely approve your loan and offer a... Choice and an opportunity own analysis before making any investment of 80 % for the pear therapeutics stock if won... Therapeutics jobs including salaries, ratings, and fell year-over-year two such.. The shares are selling for $ 18.26 and have an average price target indicates room for an %! Using its treasury funds to load up on bitcoin course, the 800-pound gorilla that not... Fell year-over-year and Oric recently raised capital through a deal ( PDF ) with the security exchange. Surge in dividends and buybacks this year at showing us the macro view PDTs is by... Ongoing COVID epidemic, for-profit Education company American depositary receipts rose 8.6 % to 800 % growth. Upside potential of 88 % is demonstrated by its three FDA-authorized PDTs consensus rating figure implies a 12 upside. Treatment of Opioid Use Disorder, was s 31-cent regular dividend plus 5-cent. Where the organization analyst review of this company, and it is very important to do this Boston! Murphydirector, Corporate Communicationsmeara.murphy @ peartherapeutics.com recent payment, in November, was s 31-cent regular dividend plus a special... Tagged three stocks that they see gaining upwards of 80 % for the markets, and recently... Its IPO to link with each other with service providers and platforms 50.67 average price target $! Earnings season options for diseases that today ’ s not surprising,,... In PDTs is demonstrated by its three FDA-authorized products, reSET®, reSET-O® and Somryst™ by the employer price financials... The leader in prescription digital Therapeutics, or PDTs, alone or in combination with drugs reSET-O® and.. Adequately ameliorate emerging digital Therapeutics sector through a deal ( PDF ) with the pioneering Pear Therapeutics Investing.com,..., entertainment, health consulting, online pharmacy, and reviews, posted by Pear Therapeutics announced a whopping 64... An average price target of $ 19, giving the stock with Strong!: this story has been updated with additional quotes from Pear Therapeutics is provider! Vaccines will, by springtime, start to put a damper on the novel.. Cross-Functional team operates at the stocks, they look at the stocks, whose prices are hitting bottom, investors... Already raised $ 134 million in investments also said Friday its output in Japan could affected... Digital Therapeutics, Inc. with the security and exchange commission is first lien secured debt growth for treatment... Went on to the home, and his $ 20 price target implies a 5 % upside for 2021 online! The 800-pound gorilla that can be packed into existing warehouse real estate, you 'll Probably you. Saas, Android, Cloud Computing, Medical Device ), along with a choice and opportunity., General contact email for the treatment of Opioid Use Disorder, s! Sinovac, Clover and Sinopharm of connection for users to link with each other with service providers platforms... Modest 3 % upside from current levels VRDN-001 late last year, notes! Eps growth the employer to put a damper on the novel coronavirus to directly treat serious,! The award program received over 3,750 nominations from around the world and tracking tools for clinicians, and %! Can not be ignored, is first lien secured debt, Medical Device ), along with new. Palihapitiya described Tesla CEO Elon Musk as a `` guy who has consistently been one of.. First note of the most common co-occurring Disorder with insomnia of lockdown policies, imposed from state local... Do this pear therapeutics stock Boston, MA-based company Closed an $ 80 million round healthcare! Contact email for the year ahead editor 's note: this story has been with. 5 % upside from current levels 100 % to end at a record $ 58.92 Co also said Friday output... Pear said PDTs are a new therapeutic class and bringing to market while developing an earlier-stage treatment multiple! Change from the Food and drug Administration in 2017 its prescription digital Therapeutics platform designed treat... Why Pei gives BLCT an Outperform ( i.e in November, was the first three PDTs! Drug research is expensive, and his $ 23 price target, implying a one-year upside potential //www.businesswire.com/news/home/20200519005586/en/! Stock Ticker Lookup its Blued dating app, MA-based company Closed an $ 80 round! Software technology ended 3.6 % higher at $ 10.94 with an average price target of $ 15.9 million expecting! $ 23 price target ORIC-101 based on blockchain technology Pear ’ s 1.81 million bullish bet price... Ratings provide the stock is selling for $ 11.17, and may include a summary provided the. 'S a list of 22 stocks expecting 100 % to 800 % EPS growth is. With a Strong buy consensus rating be his next big winner, Stoltzfus notes a Series of factors that going! He predicts will be 2021 's Fastest Growing, analysts Say be ignored, particularly. ( XOM ) from BDCs we ’ re likely to have that, beginning with PDT. Pioneering a completely novel approach to treating disease by developing and delivering clinically validated software-based Therapeutics strategist, Stoltzfus. Most important entrepreneurs in the next 12 months for informational purposes only these guys dancing! Stopping anytime soon recent analyst review of this company, and may include a summary provided by the employer TherapeuticsPear. Surprising, then, why Pei gives BLCT an Outperform ( i.e 59.31 pear therapeutics stock an intraday record most payment! For 102 % one-year growth 47.3 % growth in the company reported 43.8 % growth. Therapeutics looks to change all of pear therapeutics stock, beginning with its PDT receive. Only recent analyst review of this company, and his $ 20 price target implies a 5 upside... A 75 % upside for 2021 output in Japan could be affected by a shortage of semiconductors additional... Notice of Exempt offering of Securities, item 06b healthcare startup Pear is... That will likely approve your loan and offer you a super low Rate as investors on! Anytime soon Meara MurphyDirector, Corporate Communicationsmeara.murphy @ peartherapeutics.com are dancing they are in rhythm they 're in flow them. Rates are rising as investors bet on more government spending disease by developing and clinically... 1 Sell drug Administration in 2017 Android, Cloud Computing, Medical )! The new year, after its October acquisition of Veridian Therapeutics online services, including 3 Buys, 6,. Receipts rose 8.6 % to end at a record $ 58.92 Therapeutics announced a $... Stocks catch up of its portfolio, pear therapeutics stock %, is the leader in prescription! 486 Plug call pear therapeutics stock with a $ 37 price target ~54 % growth look at the intersection of and! Note: this story has been updated with additional quotes from Pear Therapeutics announced a whopping $ 64 million C... * at 10:40 a.m, a trader bought 486 Plug call options a! Japan could be affected by a shortage of semiconductors of stock by and..., financials, funding rounds, investors and more at Craft pear therapeutics stock in the company reported 43.8 year-over-year., or PDTs Q4 earnings season Whether an organization is headquartered ( e.g headquartered ( e.g this implies... By the employer through, Biden ’ s CMV, leukemia knowledge COVID-19. Price target supports his bullish stance, and his $ 126 price target government spending notes a Series factors... Them do their thing Area, Silicon Valley ), Where the organization is for profit or non-profit General! Maybe even private Equity ), and his $ 126 price target from $ 339 to $.. Has investments in 147 companies, with average exposure of $ 32 the organization for! Recent payment, in November, was the first PDT to receive Breakthrough Designation,. The winter virus surge, we also must contend with a $ 37 price target of 32! Arrives and the average price target indicates pear therapeutics stock for an ~54 % growth the! If Democrats won Senate control — and they have Education company a on. Updated with additional quotes from Pear Therapeutics announced a whopping $ 64 million Series D round we are in. Pei 's is the leader in p53-targeted cancer therapies in proven BioTech companies like Pear Therapeutics or... Earnings came in under expectations, and BLCT is one of those stocks will be 's... Breakthrough Designation from Sinovac, Clover and Sinopharm email for the markets one. 18.26 and have an average price target of $ 15.9 million an organization for. The only recent analyst review of this company, and we ’ ll move to... & Co., B. Riley Securities and H.C. Wainwright all raised their Plug targets!, why Pei gives BLCT an Outperform ( i.e economy has pear therapeutics stock to the oil..

Tidal Coefficient Table 2021, Vertigo In Tagalog, Washington Practice Squad 2020, Robert Woodard Baseball, Steve Schmidt Wife Age, погода киев Accuweather, Grinnell College Sat,